Oramed Pharmaceuticals Inc.
(ORMP) – NasdaqCM
1.94 | 0.01 (0.52%) |
Exchange : | NASDAQ (US Dollar) |
Ric Code : | ORMP |
Volume : | 1,575,161 |
Date : | 01-27-2023 |
* Minimum 20 minute delay See terms
–
Oramed Pharmaceuticals (NASDAQ: ORMP) has developed innovative technology to transform injectable treatments into oral therapies.
Oramed’s flagship product, an oral insulin capsule, can better the lives of millions of diabetics around the world – allowing, amongst other things, type 2 patients to begin insulin therapy earlier without fear of needles… [READ MORE >]
Oramed Announces Top-line Results from Phase 3 Trial of ORMD-0801 for the Treatment of Type 2 Diabetes
NEW YORK, Jan. 11, 2023 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, announced today top-line results from its Phase 3 randomized, double-blind, [...]
Oramed Announces Additional Positive Safety and Efficacy Data from Its Phase 2 Clinical Trial of ORMD-0801 for NASH
Achieved primary endpoint of safety and tolerability in participants with Type 2 diabetes with NASH. Oral insulin candidate demonstrates consistent trends across key secondary endpoints with reduction of liver fat, liver stiffness and lipids. Key [...]
Oramed Signs Definitive Deal with Medicox to Commercialize Oral Insulin in South Korea
Medicox to Distribute Oramed's Oral Insulin in South Korea, if approved Oramed to Receive Up to $18 Million in Developmental Milestones Oramed to Receive up to 15% Royalties on Gross Sales Large Market Potential: 1 [...]
Oramed Reports Third Quarter 2022 Financial Results
NEW YORK, Nov. 10, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. ("Oramed" or the "Company") (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today reported its [...]